Exposure to selective serotonin reuptake inhibitors and the risk of congenital malformations: a nationwide cohort study

Objectives To analyse the relation between selective serotonin reuptake inhibitor (SSRI) use and major congenital malformations, with focus on malformations of the heart. Design Register-based retrospective nationwide cohort study, using the Danish Medical Birth Registry. Setting Denmark. Participants Pregnant women in Denmark between 1997 and 2009 and their offspring. Primary outcome measures For each SSRI, ORs for major congenital malformations were estimated using multivariable logistic regression models for women exposed to an SSRI during the first trimester and for women with paused exposure during pregnancy. Results The authors identified 848 786 pregnancies; 4183 were exposed to an SSRI throughout the first trimester and 806 pregnancies paused exposure during pregnancy. Risks of congenital malformations of the heart were similar for pregnancies exposed to an SSRI throughout the first trimester, adjusted OR 2.01 (95% CI 1.60 to 2.53), and for pregnancies with paused SSRI treatment during pregnancy, adjusted OR 1.85 (95% CI 1.07 to 3.20), p value for difference: 0.94. The authors found similar increased risks of specific congenital malformations of the heart for the individual SSRIs. Furthermore, the authors found no association with dosage. Conclusions The apparent association between SSRI use and congenital malformations of the heart may be confounded by indications. The moderate absolute risk increase combined with uncertainty for causality still requires the risk versus benefit to be evaluated in each individual case.

[1]  B. Källén,et al.  Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data , 2010, Psychological Medicine.

[2]  P. Mortensen,et al.  The Danish Civil Registration System. A cohort of eight million persons. , 2006, Danish medical bulletin.

[3]  S. Pocock,et al.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. , 2007, Preventive medicine.

[4]  A. Bérard,et al.  Duration of antidepressant use during pregnancy and risk of major congenital malformations , 2008, British Journal of Psychiatry.

[5]  Wilhelmina S Kerstjens-Frederikse,et al.  First-trimester use of paroxetine and congenital heart defects: a population-based case-control study. , 2009, Birth defects research. Part A, Clinical and molecular teratology.

[6]  T. F. Andersen,et al.  The Danish National Hospital Register. A valuable source of data for modern health sciences. , 1999, Danish medical bulletin.

[7]  H. Sørensen,et al.  Maternal Use of Selective Serotonin Reuptake Inhibitors and Risk of Congenital Malformations , 2006, Epidemiology.

[8]  R. Davis,et al.  Outcomes of prenatal antidepressant exposure. , 2002, The American journal of psychiatry.

[9]  Jan M Friedman,et al.  Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. , 2007, The New England journal of medicine.

[10]  I. Petersen,et al.  Selective serotonin reuptake inhibitors and risk for major congenital anomalies. , 2012, Obstetrics and gynecology.

[11]  R. Platt,et al.  Use of antidepressant medications during pregnancy: a multisite study. , 2008, American journal of obstetrics and gynecology.

[12]  L. Køber,et al.  The pattern of use of non‐steroidal anti‐inflammatory drugs (NSAIDs) from 1997 to 2005: a nationwide study on 4.6 million people , 2008, Pharmacoepidemiology and drug safety.

[13]  B. Källén,et al.  Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations. , 2007, Birth defects research. Part A, Clinical and molecular teratology.

[14]  T. Einarson,et al.  Incidence of Major Malformations in Infants following Antidepressant Exposure in Pregnancy: Results of a Large Prospective Cohort Study , 2009, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[15]  B. Källén,et al.  Delivery outcome after the use of antidepressants in early pregnancy , 1999, European Journal of Clinical Pharmacology.

[16]  J. Olsen,et al.  Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study , 2009, BMJ : British Medical Journal.

[17]  J. Olsen,et al.  The Danish Medical Birth Registry. , 1998, Danish medical bulletin.

[18]  Tara R. Lang,et al.  Recent trends in selective serotonin reuptake inhibitor use in pregnancy. , 2008, Journal of clinical psychopharmacology.

[19]  L. de Jong-van den Berg,et al.  Do Pregnant Women Report Use of Dispensed Medications? , 2001, Epidemiology.

[20]  S. Rasmussen,et al.  Patterns of Antidepressant Medication Use Among Pregnant Women in a United States Population , 2011, Journal of clinical pharmacology.

[21]  Paul B van den Berg,et al.  Increase in use of selective serotonin reuptake inhibitors in pregnancy during the last decade, a population-based cohort study from the Netherlands. , 2008, British journal of clinical pharmacology.

[22]  M. Clementi,et al.  Paroxetine and fluoxetine in pregnancy: a prospective, multicentre, controlled, observational study. , 2008, British journal of clinical pharmacology.

[23]  W. Ray,et al.  Increasing use of antidepressants in pregnancy. , 2008, American journal of obstetrics and gynecology.

[24]  S. Hernández-Díaz,et al.  First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. , 2007, The New England journal of medicine.

[25]  T. Einarson,et al.  Prevalence of Depression During Pregnancy: Systematic Review , 2004, Obstetrics and gynecology.

[26]  C. Hertzman,et al.  Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population-based health data. , 2008, Birth defects research. Part B, Developmental and reproductive toxicology.

[27]  H. Sørensen,et al.  Improvement of drug exposure data in a registration of congenital anomalies. Pilot-study: pharmacist and mother as sources for drug exposure data during pregnancy. EuroMAP Group. Europen Medicine and Pregnancy Group. , 1999, Teratology.

[28]  C. Even,et al.  [Antepartum depression: prevalence, diagnosis and treatment]. , 2010, L'Encephale.

[29]  S. Sabroe,et al.  Identification of patients treated with strong analgesics: An assessment of two Danish information systems with respect to epidemiological research , 1996, Journal of Medical Systems.

[30]  R. Platt,et al.  Risks of congenital malformations and perinatal events among infants exposed to antidepressant medications during pregnancy , 2007, Pharmacoepidemiology and drug safety.

[31]  A. Olshan,et al.  First trimester paroxetine use and the prevalence of congenital, specifically cardiac, defects: a meta-analysis of epidemiological studies. , 2010, Birth defects research. Part A, Clinical and molecular teratology.

[32]  T. Einarson,et al.  Paroxetine and congenital malformations: meta-Analysis and consideration of potential confounding factors. , 2007, Clinical therapeutics.

[33]  Mark Walker,et al.  Selective serotonin reuptake inhibitors and adverse pregnancy outcomes. , 2006, American journal of obstetrics and gynecology.

[34]  Eurocat.  European Surveillance of Congenital Anomalies (EUROCAT) , 2012 .

[35]  Lucie Blais,et al.  First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage. , 2007, Birth defects research. Part B, Developmental and reproductive toxicology.

[36]  C. Pedersen,et al.  The Danish Civil Registration System , 2011, Scandinavian journal of public health.

[37]  H. Sørensen,et al.  The Danish prescription registries. , 1997, Danish medical bulletin.

[38]  Tara R. Lang,et al.  Congenital heart disease associated with selective serotonin reuptake inhibitor use during pregnancy. , 2009, Mayo Clinic proceedings.

[39]  M. Nørgaard,et al.  Use of selective serotonin-reuptake inhibitors during early pregnancy and risk of congenital malformations: updated analysis , 2010, Clinical epidemiology.

[40]  K. Ormond,et al.  Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study. , 1998, JAMA.

[41]  P. Neuvonen,et al.  Risks Associated With Selective Serotonin Reuptake Inhibitors in Pregnancy , 2005, Obstetrics and gynecology.

[42]  L. Jong‐van den Berg,et al.  Prevalence and patterns of antidepressant drug use during pregnancy , 2006, European Journal of Clinical Pharmacology.

[43]  B. Källén,et al.  Antidepressant drugs during pregnancy and infant congenital heart defect. , 2006, Reproductive toxicology.

[44]  S. Ephross,et al.  Paroxetine in the first trimester and the prevalence of congenital malformations , 2007, Pharmacoepidemiology and drug safety.

[45]  B. Källén,et al.  Delivery Outcome in Relation to Maternal Use of Some Recently Introduced Antidepressants , 2007, Journal of clinical psychopharmacology.